Elucidating HIV and HIV-treatment Associated Metabolic/Endocrine Dysfunction (R01 Clinical Trial Optional)

Funder: National Institutes of Health

Budget: Negotiable

Due Date: March 13, 2018

Opportunity: RFA-DK-17-036

The goal of this Funding Opportunity Announcement (FOA) is to support innovative research to elucidate the role of HIV infection, including relevant host conditions or antiretroviral therapy, on metabolic and endocrine dysfunction, as well as to support innovative research delineating the pathophysiology, etiology, risk or protective factors, and potential strategies to prevent, treat, or reverse endocrine and metabolic dysfunction in HIV-infected individuals. This FOA supports both mechanistic research and clinical trials. Proposed projects must be related to the mission of the Division of Diabetes, Endocrinology, and Metabolic Diseases within NIDDK (DEM/NIDDK).

Leave a Reply